vs

Side-by-side financial comparison of CASTLE BIOSCIENCES INC (CSTL) and CareTrust REIT, Inc. (CTRE). Click either name above to swap in a different company.

CareTrust REIT, Inc. is the larger business by last-quarter revenue ($134.9M vs $83.7M, roughly 1.6× CASTLE BIOSCIENCES INC). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs -17.4%, a 99.9% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs -4.9%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs -1.9%).

Castle Biosciences Inc. is a commercial-stage diagnostic firm that develops and markets proprietary, clinically actionable tests for dermatological conditions such as melanoma and other skin cancers, plus rare diseases. It operates mainly in the U.S. healthcare market, focusing on segments with high unmet need for more accurate diagnostics to guide treatment choices.

Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

CSTL vs CTRE — Head-to-Head

Bigger by revenue
CTRE
CTRE
1.6× larger
CTRE
$134.9M
$83.7M
CSTL
Growing faster (revenue YoY)
CTRE
CTRE
+60.0% gap
CTRE
55.1%
-4.9%
CSTL
Higher net margin
CTRE
CTRE
99.9% more per $
CTRE
82.5%
-17.4%
CSTL
Faster 2-yr revenue CAGR
CTRE
CTRE
Annualised
CTRE
46.2%
-1.9%
CSTL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CSTL
CSTL
CTRE
CTRE
Revenue
$83.7M
$134.9M
Net Profit
$-14.5M
$111.3M
Gross Margin
Operating Margin
Net Margin
-17.4%
82.5%
Revenue YoY
-4.9%
55.1%
Net Profit YoY
43.8%
113.5%
EPS (diluted)
$-0.49
$0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSTL
CSTL
CTRE
CTRE
Q1 26
$83.7M
Q4 25
$87.0M
$134.9M
Q3 25
$83.0M
$132.4M
Q2 25
$86.2M
$112.5M
Q1 25
$88.0M
$96.6M
Q4 24
$86.3M
$86.9M
Q3 24
$85.8M
$77.4M
Q2 24
$87.0M
$68.9M
Net Profit
CSTL
CSTL
CTRE
CTRE
Q1 26
$-14.5M
Q4 25
$111.3M
Q3 25
$-501.0K
$74.9M
Q2 25
$4.5M
$68.5M
Q1 25
$-25.8M
$65.8M
Q4 24
$52.1M
Q3 24
$2.3M
$33.4M
Q2 24
$8.9M
$10.8M
Gross Margin
CSTL
CSTL
CTRE
CTRE
Q1 26
Q4 25
79.0%
Q3 25
77.5%
Q2 25
79.5%
Q1 25
81.4%
Q4 24
81.3%
Q3 24
81.8%
Q2 24
83.3%
Operating Margin
CSTL
CSTL
CTRE
CTRE
Q1 26
Q4 25
-4.4%
Q3 25
-8.2%
58.1%
Q2 25
-4.9%
61.3%
Q1 25
-31.7%
Q4 24
4.7%
Q3 24
5.9%
43.0%
Q2 24
5.8%
15.1%
Net Margin
CSTL
CSTL
CTRE
CTRE
Q1 26
-17.4%
Q4 25
82.5%
Q3 25
-0.6%
56.6%
Q2 25
5.2%
60.9%
Q1 25
-29.4%
68.1%
Q4 24
60.0%
Q3 24
2.6%
43.2%
Q2 24
10.3%
15.6%
EPS (diluted)
CSTL
CSTL
CTRE
CTRE
Q1 26
$-0.49
Q4 25
$-0.06
$0.52
Q3 25
$-0.02
$0.35
Q2 25
$0.15
$0.35
Q1 25
$-0.90
$0.35
Q4 24
$0.32
$0.30
Q3 24
$0.08
$0.21
Q2 24
$0.31
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSTL
CSTL
CTRE
CTRE
Cash + ST InvestmentsLiquidity on hand
$63.8M
$198.0M
Total DebtLower is stronger
$10.1M
$894.2M
Stockholders' EquityBook value
$461.4M
$4.0B
Total Assets
$547.8M
$5.1B
Debt / EquityLower = less leverage
0.02×
0.22×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSTL
CSTL
CTRE
CTRE
Q1 26
$63.8M
Q4 25
$299.5M
$198.0M
Q3 25
$287.5M
$712.5M
Q2 25
$275.9M
$306.1M
Q1 25
$275.2M
$26.5M
Q4 24
$293.1M
$213.8M
Q3 24
$95.0M
$377.1M
Q2 24
$85.6M
$495.1M
Total Debt
CSTL
CSTL
CTRE
CTRE
Q1 26
$10.1M
Q4 25
$10.1M
$894.2M
Q3 25
$10.0M
$893.8M
Q2 25
$10.0M
$1.2B
Q1 25
$10.0M
$822.1M
Q4 24
$10.0M
$396.9M
Q3 24
$10.0M
$396.7M
Q2 24
$10.0M
$671.1M
Stockholders' Equity
CSTL
CSTL
CTRE
CTRE
Q1 26
$461.4M
Q4 25
$470.9M
$4.0B
Q3 25
$467.0M
$4.0B
Q2 25
$455.4M
$3.3B
Q1 25
$440.3M
$2.9B
Q4 24
$455.8M
$2.9B
Q3 24
$441.1M
$2.4B
Q2 24
$423.9M
$1.9B
Total Assets
CSTL
CSTL
CTRE
CTRE
Q1 26
$547.8M
Q4 25
$578.6M
$5.1B
Q3 25
$562.8M
$5.1B
Q2 25
$544.7M
$4.7B
Q1 25
$501.7M
$3.9B
Q4 24
$531.2M
$3.4B
Q3 24
$514.6M
$2.9B
Q2 24
$487.3M
$2.7B
Debt / Equity
CSTL
CSTL
CTRE
CTRE
Q1 26
0.02×
Q4 25
0.02×
0.22×
Q3 25
0.02×
0.22×
Q2 25
0.02×
0.35×
Q1 25
0.02×
0.28×
Q4 24
0.02×
0.14×
Q3 24
0.02×
0.16×
Q2 24
0.02×
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSTL
CSTL
CTRE
CTRE
Operating Cash FlowLast quarter
$-22.1M
$394.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.54×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSTL
CSTL
CTRE
CTRE
Q1 26
$-22.1M
Q4 25
$26.9M
$394.0M
Q3 25
$22.6M
$100.9M
Q2 25
$20.8M
$100.8M
Q1 25
$-6.0M
$71.4M
Q4 24
$24.4M
$244.3M
Q3 24
$23.3M
$67.2M
Q2 24
$24.0M
$53.0M
Free Cash Flow
CSTL
CSTL
CTRE
CTRE
Q1 26
Q4 25
$19.7M
Q3 25
$7.8M
Q2 25
$11.6M
Q1 25
$-10.8M
Q4 24
$16.8M
Q3 24
$17.0M
Q2 24
$18.8M
FCF Margin
CSTL
CSTL
CTRE
CTRE
Q1 26
Q4 25
22.7%
Q3 25
9.4%
Q2 25
13.4%
Q1 25
-12.2%
Q4 24
19.5%
Q3 24
19.8%
Q2 24
21.6%
Capex Intensity
CSTL
CSTL
CTRE
CTRE
Q1 26
Q4 25
8.3%
Q3 25
17.9%
Q2 25
10.7%
Q1 25
5.4%
Q4 24
8.8%
Q3 24
7.4%
Q2 24
6.0%
Cash Conversion
CSTL
CSTL
CTRE
CTRE
Q1 26
Q4 25
3.54×
Q3 25
1.35×
Q2 25
4.60×
1.47×
Q1 25
1.08×
Q4 24
4.68×
Q3 24
10.29×
2.01×
Q2 24
2.69×
4.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons